Definitive Healthcare (DH) has released its financial outcomes for the second quarter of 2026, revealing strong profitability and margin performance that exceeded expectations, even as total revenue saw a 9% year-over-year decrease. The company's strategic framework, built on enhancing data quality, streamlining system integrations, ensuring client success, and fostering innovation, is actively being implemented. While the provider and diversified business units, which collectively account for over 60% of the firm's revenue, are showing signs of stability and recovery, the life sciences division continues to present a challenge to overall growth. A key development is the initial rollout of the AI-powered Turbo platform, designed to transition from basic data retrieval to autonomous decision-making, with the goal of bolstering customer loyalty and capitalizing on the expanding digital activation ecosystem.
During this period, the company's financial discipline was evident, with adjusted EBITDA reaching $14.6 million, representing a 26% margin, and non-GAAP earnings per share at $0.05. Furthermore, Definitive Healthcare generated $11.6 million in unlevered free cash flow for the quarter, contributing to $50 million over the trailing 12 months, underscoring its capacity for robust cash generation. CEO Kevin Coop highlighted a noteworthy improvement in net dollar retention rates for the second consecutive quarter and reported the biopharma segment's strongest new business performance in three years (excluding Q4), which included the reacquisition of four former clients. This success reinforces the company's conviction that superior data quality and service ultimately provide greater long-term value than lower-priced alternatives. The firm is also making significant strides in its strategic pillars, including the introduction of ACE 3.0, an AI-driven estimation methodology for healthcare claims, and the expansion of its practice location data to over 4.4 million verified sites, significantly improving data precision for various commercial activities. Additionally, the company has accelerated system integrations by over 50% year-over-year while reducing integration time by more than half, exemplified by a successful native integration with Veeva Vault CRM for life sciences clients.
Looking ahead, Definitive Healthcare is intensifying its focus on innovation and digital engagement, particularly with the pilot launch of its Turbo platform in August 2026, aiming for general availability by year-end. This AI-powered platform is expected to revolutionize how healthcare teams access and utilize data, enabling more informed commercial, strategic, and product decisions through natural language processing. Despite a cautious revenue outlook for the full year 2026, projected at $220 million to $222 million (an 8% to 9% decline), the company has raised its full-year profit guidance, with adjusted EBITDA anticipated to be between $57 million and $59 million. This upward adjustment reflects effective cost management and strategic investments in high-growth areas, demonstrating a commitment to maintaining strong margins while paving the way for future growth. The company anticipates Turbo will primarily influence 2027 revenues but expects it to positively impact retention rates in the latter part of 2026, especially during key renewal periods. Discussions about the platform's commercial model are ongoing, with considerations for bundled retention uplift, premium SKUs, and usage-based pricing tailored to diverse customer segments.
Definitive Healthcare's unwavering dedication to innovation, data excellence, and client satisfaction positions it for a future of sustainable growth and continued leadership in the healthcare intelligence sector. The strategic embrace of artificial intelligence, not merely as a product feature but as a company-wide transformative force, promises to refine operations, enhance decision-making, and deepen customer relationships, ultimately yielding enduring value for shareholders.
